3Daughters secures $2million funding to advance its pain-free contraception insertion

3Daughters wants to radically transform the IUD market by eliminating the major barrier to adoption - pain during insertion.

For decades women have had to ‘put up with’ pain during the insertion of birth control such as IUDs.

US-based startup 3Daughters has now secured $2million in the first tranche of its seed financing round to address this issue.

3Daughters wants to radically transform the IUD market by eliminating the major barrier to adoption - pain during insertion.

The current T-shaped plastic frame for IUDs has been around for over 40 years and has hardly changed. IUDs are highly effective and women’s preferred choice of contraception. However, there is a pervasive ‘fear factor’ that prevents women from selecting an IUD.

Instead, the 3Daughters design is a unique and frameless magnetic non-hormonal IUD, based on physics and geometry, for targeted therapy directly into the uterus. It does not have dangling strings but naturally conforms to the body and ‘floats’ in the uterus.

Combined with a novel and patented i-Slider™ for insertion and r-Slider™, a simple magnetic retriever, 3Daughters will be eliminating a number of pain points that keep women from getting one of the most effective forms of birth control.

Proceeds from the funding will be used to advance the Company’s lead IUD asset, 3D-001, through an IND filing followed by a Phase 1 clinical trial this year.

Mary Beth Cicero, Co-Founder and CEO of 3Daughters, said:

“We are thrilled to have garnered such strong support from our existing and new investors, all of whom share our vision of solving health issues for women. This investment marks the next chapter for 3Daughters and allows us to execute our streamlined development plans to move into the clinic. With this funding, we are getting closer to our promise to address significant and neglected issues, like IUD insertion pain, that women have been putting up with for over 50 years.”

Changing the dynamic

This funding round was led by Thairm Bio, with a group of life science investors, and joined by the Argosy Foundation, Wexford Science and Technology, LLC, UMass Amherst, and other undisclosed investors.

Thairm Bio CEO Mark Bamforth said:

“The lack of innovation in women’s health and the significant need 3Daughters is addressing drew me to this investment. It is clear that women’s health gets overlooked from an investment perspective and I want to be a part in changing that dynamic.

“Given the apparent urgency for new and effective contraceptive options and the pain women experience with IUDs, I recognized the need and formed an investment vehicle with my colleagues to help fund this important innovation for women.”

3Daughters now aims to bring in a further $1m for its seed round, bringing the total to $3m.